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INTRODUCTION 
Cardiovascular disease is the leading cause of morbidity and 
mortality in dialysis patients, accounting for 50%of deaths[1]. Pulmonary 
hypertension (PHT) comprises a group of clinical and pathophysiological 
entities with similar featuresbut a variety of underlying causes. There are 
several etiologies for PHT. Pulmonary hypertension (PHT) can be the result 
of heart, lung or systemic disorders. Regardlessof the etiology, morbidity 
and mortality from long-standingPHT exceed that expected from the 
causative condition [2].  
PHT was frequently found in patients with chronic renal failure 
(CRF).Review of literature showed that in one study, PHT was found in 
40% of patients with end stage renal disease (ESRD) onchronic 
hemodialysis therapy via arteriovenous access[5, 6]. Adekunle et al. [7] stated 
that PHT is an independent predictor of mortality in ESRD patients. 
PHT involvesvasoconstriction and obliteration of the lumen ofsmall 
vessels in the lungs by plexiform lesions resultingin increased resistance to 
flow [2]. Proposed mechanisms for the formation of the plexiform lesion 
includedysregulation of endothelial growth and angiogenicresponse to local 
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triggers[3]. Hormonal and metabolic derangement associated with ESRD 
might lead to pulmonary arterialvasoconstriction and an increase of the 
pulmonaryvascular resistance[4]. 
Pulmonary artery pressure (PAP) may be further increasedby high 
cardiac output resulting from the arteriovenousaccess itself and also 
worsened by commonly occurring anemia and fluid overload [8]. Subclinical 
left ventriculardysfunction also occurs in patients with ESRD, and 
isevidenced as abnormal myocardial diastolic rather thansystolic 
dysfunction [9]. 
Local vascular tone and function of pulmonary vesselsare regulated 
by the balance between vasodilators, such as nitric oxide, and 
vasoconstrictors, such as thromboxane[10]. Patients with CRF show an 
endothelial dysfunctionrelated to defective nitric oxide activity, which is 
notcorrected by hemodialysis (HD) [11].Increased brain natriuretic hormone 
is associated withage, left ventricular hypertrophy, renal failure, and 
PHT.N-terminal pro-brain natriuretic peptide (NT-proBNP)is a byproduct of 
brain natriuretic peptide (BNP) that hasbeen shown to be of prognostic 
value in PHT[15]. 
 
9 
 
 
 
 
 
AIM  
10 
 
 
AIM 
 
In this study, we aim to find the prevalence of PHT in patients with 
ESRD and compare the incidence of PHT between those on hemodialysis 
and those on conservative management. We also compare the biochemical 
data of the patients with and without PHT to find out any possible 
associations. 
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REVIEW OF LITERATURE 
 
INTRODUCTION 
 Pulmonary hypertension (PHT) is characterized by elevated 
pulmonary arterial pressure and secondary right ventricular failure. It is a 
life-threatening condition with a poor prognosis if untreated. 
DEFINITION 
 The definition of PHT is based upon right heart catheterization 
measurements. PHT is defined as a mean pulmonary artery pressure 
greater than 25 mmHg at rest [13]. A mean pulmonary artery pressure of 8 to 
20 mmHg at rest is considered normal, while a mean pulmonary artery 
pressure of 21 to 24 mmHg at rest has uncertain clinical implications. 
 Two definitions that were previously accepted are no longer used. 
They include a mean pulmonary artery pressure greater than 30 mmHg 
with exercise (measured by right heart catheterization) [14] and a systolic 
pulmonary artery pressure greater than 40 mmHg (measured by Doppler 
echocardiography) [15]. The latter corresponds to a tricuspid regurgitant 
velocity of 3.0 to 3.5 m/sec. 
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CLASSIFICATION 
 Like its definition, the classification of PHT has changed. PHT was 
previously classified as either idiopathic pulmonary arterial hypertension 
(IPAH, formerly called primary pulmonary hypertension) or secondary PHT. 
However, it became clear that some forms of secondary PHT closely 
resemble IPAH in their histopathological features, natural history, and 
response to treatment. In an attempt to organize PHT on a mechanistic 
basis, the World Health Organization (WHO) classified PHT into five groups 
[16]. 
Updated clinical classification of pulmonary hypertension (Dana 
Point, 2008) 
1. Pulmonary arterial hypertension (PAH)  
1.1. Idiopathic PAH   
1.2. Heritable   
1.2.1. BMPR2   
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)   
1.2.3. Unknown   
1.3. Drug- and toxin-induced   
1.4. Associated with   
1.4.1. Connective tissue diseases   
1.4.2. HIV infection   
1.4.3. Portal hypertension   
1.4.4. Congenital heart diseases   
1.4.5. Schistosomiasis 
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1.4.6. Chronic hemolytic anemia   
1.5 Persistent pulmonary hypertension of the newborn   
1′. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)  
2. Pulmonary hypertension owing to left heart disease  
2.1. Systolic dysfunction   
2.2. Diastolic dysfunction   
2.3. Valvular disease   
 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia  
3.1. Chronic obstructive pulmonary disease   
3.2. Interstitial lung disease   
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern   
3.4. Sleep-disordered breathing   
3.5. Alveolar hypoventilation disorders   
3.6. Chronic exposure to high altitude   
3.7. Developmental abnormalities   
4. Chronic thromboembolic pulmonary hypertension (CTEPH)  
5. Pulmonary hypertension with unclear multifactorial mechanisms  
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders   
5.4. Others: tumoral obstruction, fibrosingmediastinitis, chronic renal failure on dialysis   
 
ALK1: activin receptor-like kinase type 1; BMPR2: bone morphogenetic protein receptor type 2; HIV: 
human immunodeficiency virus. 
Reproduced from: Simonneau, G, Robbins, IM, Beghetti, M, et al. Updated Clinical Classifications of 
Pulmonary Hypertension. J Am CollCardiol 2009; 54:S43. Illustration used with the permission of Elsevier 
Inc. All rights reserved. 
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Group 1 PAH—―Pulmonary arterial hypertension (PAH)". 
This group consists of sporadic IPAH, heritable IPAH, and PAH due 
to diseases that localize to small pulmonary muscular arterioles. These 
include connective tissue diseases, HIV infection, portal hypertension, 
congenital heart disease, schistosomiasis, chronic hemolytic anemia, 
persistent pulmonary hypertension of the newborn, pulmonary veno-
occlusive disease, and pulmonary capillary hemangiomatosis[16]. 
Drug- and toxin-induced PAH is also considered group 1 PAH. 
Exposures to the following drugs are considered definite risk factors for 
PAH: aminorex, fenfluramine, dexfenfluramine, and toxic rapeseed oil [16]. 
In contrast, drugs that are considered likely or possible risk factors for PAH 
include amphetamines, L-tryptophan, methamphetamines, cocaine, 
phenylpropanolamine, St. John's Wort, chemotherapeutic agents, and 
selective serotonin reuptake inhibitors. 
The hemodynamic parameters that characterize PAH include the 
following [16]: 
•Mean pulmonary artery pressure (mPAP) >25 mmHg at rest 
•Pulmonary capillary wedge pressure (PCWP) <15 mmHg 
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Supportive data include an increased pulmonary vascular resistance 
and transpulmonary gradient. The transpulmonary gradient is defined as 
the difference between the mean pulmonary artery pressure and the mean 
pulmonary capillary wedge pressure. 
Group 2 PH — "Pulmonary hypertension owing to left heart disease."  
PH due to systolic dysfunction, diastolic dysfunction, or valvular heart 
disease is included in this group [16]. 
Group 3 PH — "Pulmonary hypertension owing to lung diseases or 
hypoxemia." 
This group includes PHT due to chronic obstructive pulmonary 
disease, interstitial lung disease, other pulmonary diseases with a mixed 
restrictive and obstructive pattern, sleep-disordered breathing, alveolar 
hypoventilation disorders, and other causes of hypoxemia [16]. 
Group 4 PH — "Chronic thromboembolic pulmonary hypertension." 
This group includes patients with PHt due to thromboembolic 
occlusion of the proximal or distal pulmonary vasculature [16]. 
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Group 5 PH — "Pulmonary hypertension with unclear multifactorial 
mechanisms." 
These patients have PHT caused by hematologic disorders (eg, 
myeloproliferative disorders), systemic disorders (eg, sarcoidosis), 
metabolic disorders (eg, glycogen storage disease), or miscellaneous 
causes [16]. 
In the discussion that follows, PAH is used exclusively to discuss 
group 1, whereas PH is used to discuss groups 2 through 5. In addition, 
PHt is used when referring to all groups collectively. 
EPIDEMIOLOGY 
 The prevalence of group 1 PAH in the general population is estimated 
to be 15 cases per one million adults [17]. Similar estimates have not been 
performed for the five groups of PHT collectively. The prevalence of PHT 
appears to vary widely among specific populations of patients: 
 Systemic sclerosis (SSc, formerly called scleroderma) — An 
observational study of 794 patients with systemic sclerosis reported 
PAH in 12 percent of patients [18]. (See "Pulmonary vascular disease 
in systemic sclerosis (scleroderma): Definition, classification, risk 
factors, screening, and prognosis".) 
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 Portal hypertension — An observational study of 507 patients with 
portal hypertension reported PAH (ie, portopulmonary hypertension) 
in 2 percent of patients [19], while a more recent study reported PAH in 
about 6 percent [20]. Prevalence increases as the severity of the 
underlying cause of the portal hypertension (usually liver disease) 
worsens. (See "Portopulmonary hypertension".) 
 Congenital heart disease — Congenital heart disease occurs in 8 out 
of every 1000 live births. Approximately 30 percent of children who do 
not have their congenital heart disease repaired will develop PAH [21]. 
(See "Evaluation and prognosis of Eisenmenger syndrome", section 
on 'Evaluation for congenital heart disease related pulmonary arterial 
hypertension'.) 
 Obstructive sleep apnea (OSA) — A review of eight studies estimated 
that the prevalence of mild PH is 15 to 20 percent among patients 
with OSA [22]. (See "Cardiovascular effects of obstructive sleep 
apnea".) 
The only national surveillance data available was collected from patients 
with all groups of PH from 1980 to 2002 [23]. It is unclear how changes in 
disease recognition, reporting, and treatment during this period impacted 
the results of this study. 
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The death rate increased from 5.2 to 5.4 per 100,000 population. The 
increase was greatest in African-Americans (4.6 to 7.3 per 100,000 
population) and women (3.3 to 5.5 per 100,000 population). The death rate 
decreased in men (8.2 to 5.4 per 100,000 population) and remained stable 
in Caucasians (5.3 per 100,000 population). The most common cause of 
death was chronic lower respiratory disease from 1980 until 1999. 
Thereafter, PHT itself was the most common cause of death. 
The hospitalization rate increased more than two-fold (40.8 to 90.1 per 
100,000 population). The most common cause of hospitalization from 1980 
until 1994 was chronic lower respiratory disease. Heart failure was the 
most common cause of hospitalization after 1994. 
ETIOLOGIES 
 There are numerous causes of PAH including IPAH (both sporadic 
and hereditary), drugs and toxins, connective tissue diseases, HIV 
infection, portal hypertension, and congenital heart disease. Similarly, there 
exist many causes of PH including left heart disease, chronic obstructive 
pulmonary disease (COPD), interstitial lung disease, sleep related 
breathing disorders (eg, obstructive sleep apnea), and chronic 
thromboembolic pulmonary hypertension. A discussion of each follows. 
20 
 
Pulmonary arterial hypertension (PAH) — The following are causes of 
group 1 PAH. 
 Idiopathic pulmonary arterial hypertension (IPAH) — IPAH exists 
when an underlying cause of the PAH cannot be identified. It is 
usually sporadic, with only 6 to 10 percent of patients having 
hereditary disease in most series. 
 
Abnormal bone morphogenetic protein receptor type II (BMPR2) 
appears to play an important role in the pathogenesis of IPAH. In 
sporadic IPAH, up to 25 percent of patients have abnormal BMPR2 
structure or function [24-26]. In hereditary IPAH, the gene that encodes 
BMPR2 (IPAH1) appears to be transmitted as an autosomal 
dominant trait with incomplete penetrance [19,27-31]. In one study of 19 
patients with hereditary IPAH, mutations likely to disrupt function of 
BMPR2 were found in nine patients [30]. Abnormal pulmonary vascular 
responses to exercise have been documented in asymptomatic 
carriers of IPAH1 [32]. 
 
Hereditary IPAH may be underdiagnosed. In one study, five 
apparently unrelated families (almost 400 individuals) were linked by 
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pedigree analysis to a pair of common ancestors [33]. Among these 
families, 18 individuals were found to have hereditary IPAH, 
determined by the identification of identical BMP receptor type II 
mutations. Twelve of these subjects had been initially classified as 
having sporadic IPAH.  
 
 Drugs and toxins — Appetite suppressants (eg, fenfluramine, 
dexfenfluramine, and diethylpropion) increase the risk of developing 
PAH [24,34-37]. In a case control study that compared 95 patients with 
PAH to 335 control patients, appetite suppressants increased the risk 
of PAH (odds ratio 6.3, 95% CI 3.0-13.2) [24]. The risk was particularly 
high when the appetite suppressants were used in the preceding year 
or for more than three months. 
 
Appetite suppressant use reported by patients with all types of PHT is 
greater than that reported by the general population, suggesting that 
appetite suppressants may initiate PHT in patients with underlying 
conditions that are associated with PHT, or that obesity is associated 
with PHT[25]. 
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Chronic use of cocaine or amphetamines, either inhaled or 
intravenous, has also been associated with PAH [28,34,38,39]. In one 
study, cocaine or amphetamine use increased the risk of developing 
PAH approximately three times [34]. PAH has also been associated 
with recreational use of the designer amphetamine analog, 4-methyl-
aminorex (ie, ice, euphoria, U-4-E-uh) [40], as well as 
methamphetamines, toxic rapeseed oil, and benfluorex[41]. 
 Connective tissue disease — Systemic sclerosis (SSc, also called 
scleroderma) causes PAH by obliteration of alveolar capillaries and 
narrowing of small arteries and arterioles due to pulmonary vascular 
disease and interstitial fibrosis. Isolated PAH appears to be more 
common in patients with limited SSc compared to patients with 
diffuse cutaneous SSc[42]. Rheumatoid arthritis and systemic lupus 
erythematosus (SLE) can also lead to fibrous obliteration of the 
pulmonary vascular bed. There is a marked female predominance 
and a frequent association with the Raynaud phenomenon in patients 
with SLE who develop PAH [26]. 
 Human immunodeficiency virus (HIV) — PAH is a rare complication 
of HIV infection, occurring in approximately 1 out of every 200 HIV-
infected patients (0.5 percent) [43-45]. This is 6- to 12-times greater 
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than the prevalence of PAH in individuals without HIV infection. The 
cause of HIV-related PAH is uncertain, but viral and host factors both 
likely play an important role. HIV-related PAH is discussed in detail 
separately.  
 Portal hypertension — PAH associated with portal hypertension is 
referred to as portopulmonary hypertension. It is discussed in detail 
elsewhere. 
 Congenital heart disease — PAH due to congenital heart disease is 
due to pulmonary blood volume overload due to intracardiac 
shunting. Left to right shunts are most common, especially due to 
large (nonrestrictive) ventricular septal defects (VSD). PAH also 
occurs in patients with atrial septal defects (ASD). Noninvasive 
imaging — including transthoracic echocardiography, 
transesophageal echocardiography (TEE), and magnetic resonance 
imaging (MRI) — can be used to characterize cardiac anatomy and 
function in patients with congenital heart defects. 
Pulmonary hypertension (PH) — The following are causes of group 2, 
group 3, group 4, or group 5 PHT. 
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 Left heart disease — Left atrial hypertension (ie, an elevated 
pulmonary capillary wedge pressure) requires an increased 
pulmonary artery systolic pressure to maintain an adequate driving 
force across the pulmonary vasculature. The degree of PHT that 
results from any given level of left atrial hypertension varies greatly 
from individual to individual. This reflects the multiple impediments to 
normal pulmonary vascular flow that can exist, including reactive 
vasoconstriction, vascular remodeling, and left atrial hypertension. 
 
Causes of left atrial hypertension include left ventricular systolic or 
diastolic dysfunction, mitral and aortic valve disease, restrictive 
cardiomyopathy, constrictive pericarditis, and left atrial myxoma. 
 
Heart failure and dilated cardiomyopathy are common causes of 
PHT. As an example, in a study of 108 patients with dilated 
cardiomyopathy, 26 percent had a pulmonary artery systolic pressure 
above 40 mmHg, as determined by echocardiography [46]. The PHT 
was associated with a greater likelihood of death or hospitalizations 
(89 versus 32 percent). Multiple factors contribute to cardiomyopathy-
associated PHT including chronic pulmonary venous congestion, 
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recurrent transient hypoxemia, and sleep-disordered breathing [47]. 
 
The importance of mitral regurgitation as a cause of PHT was shown 
in a study of 41 patients with isolated severe mitral regurgitation [48]. 
PHT was identified in 76 percent of patients, of which 17 percent had 
a pulmonary artery systolic pressure greater than 70 mmHg. 
 Chronic Obstructive Pulmonary Disease (COPD) — PHT is a 
common complication of COPD with a significant impact on outcome 
[49-51]. As an example, one study reported a five-year survival rate less 
than 10 percent among patients with COPD and a mean pulmonary 
arterial pressure greater than 45 mmHg, compared to a five-year 
survival rate greater than 90 percent among patients with COPD and 
a pulmonary arterial pressure less than 25 mmHg [51]. The prevalence 
of PH in patients with COPD is more strongly associated with 
hypoxemia than symptoms or abnormal lung function [51]. 
 Interstitial lung disease (ILD) — ILD-related PHT can exist when ILD 
is mild, but it is more common when hypoxemia and severe 
pulmonary dysfunction exist. ILD-related PH is reviewed separately.  
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 Sleep related breathing disorders — Obstructive sleep apnea (OSA) 
is the sleep related breathing disorder that is most often associated 
with PHT. Untreated OSA alone is associated with mild PHT. 
However, it may be associated with significant PHT when combined 
with obesity hypoventilation syndrome (severe obesity, diminished 
central respiratory drive, and daytime hypoxemia) or other causes of 
hypoxemia. These patients have a significant risk of mortality due to 
progressive PHT, corpulmonale, or arrhythmias, although the 
magnitude of the risk is uncertain [52,56]. 
 Chronic thromboembolic disease — Chronic proximal PE may cause 
severe PH in a small number of patients. The emboli are often 
asymptomatic and the resting arterial oxygen level may be normal; 
however, virtually all patients demonstrate oxyhemoglobin 
desaturation with exercise [54,55]. 
Pulmonary angiography is unnecessary if a ventilation-perfusion 
(V/Q) scan is normal because a normal V/Q scan accurately excludes 
thromboembolic disease [56]. When thromboembolic disease exists, 
however, pulmonary angiography is necessary to define the extent of 
disease because perfusion scans tend to underestimate the extent of 
proximal embolization [57]. 
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CLINICAL MANIFESTATIONS 
  In this section, the symptoms and signs of PHT are described. These 
findings may be difficult to elucidate in patients with PHT that is caused by 
an underlying condition, because manifestations of the underlying disease 
frequently obscure those of the PHT. 
History 
Most patients with PHT initially experience exertional dyspnea, 
lethargy, and fatigue, which are due to an inability to increase cardiac 
output with exercise [58,59]. As the PHT progresses and right ventricular 
failure develops, exertional chest pain (ie, angina), exertional syncope, and 
peripheral edema may develop. In most circumstances, angina is due to 
subendocardialhypoperfusion caused by increased right ventricular wall 
stress and myocardial oxygen demand. However, angina is occasionally 
caused by dynamic compression of the left main coronary artery by an 
enlarged pulmonary artery; this risk is greatest for patients with a 
pulmonary artery trunk at least 40 mm in diameter [60-62]. 
Passive hepatic congestion may cause anorexia and abdominal pain 
in the right upper quadrant. Less common symptoms of PHT include 
cough, hemoptysis, and hoarseness (ie, Ortner's syndrome) due to 
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compression of the left recurrent laryngeal nerve by a dilated main 
pulmonary artery. 
Physical examination  
The initial physical finding of PHT is usually increased intensity of the 
pulmonic component of the second heart sound, which may even become 
palpable. The second heart sound is narrowly split or single in patients with 
PHT and preserved right ventricular function. Splitting of the second heart 
sound widens as the right ventricle fails or if right bundle branch block 
develops.  
Auscultation of the heart may also reveal a systolic ejection murmur 
and, in more severe disease, a diastolic pulmonic regurgitation murmur. 
The right-sided murmurs and gallops are augmented with inspiration.  
Right ventricular hypertrophy is characterized by a prominent A wave 
in the jugular venous pulse, associated with a right-sided fourth heart 
sound, and either a left parasternal heave or a downward subxiphoid thrust. 
Right ventricular failure results in systemic venous hypertension. This 
can lead to a variety of findings such as elevated jugular venous pressure, 
a right ventricular third heart sound, and a high-pitched tricuspid regurgitant 
murmur accompanied by a prominent V wave in the jugular venous pulse if 
29 
 
tricuspid regurgitation is present. In addition, hepatomegaly, a pulsatile 
liver, peripheral edema, ascites, and pleural effusion may exist [63,64].  
Some patients with PHT due to severe COPD develop edema even in 
the absence of right heart failure [67]. The pathogenesis of edema in such 
patients is not well understood [66,67]. It has been hypothesized that edema 
may develop in these patients due to hypercapnia or hypoxemia. 
Hypercapnia is associated with an appropriate increase in proximal 
bicarbonate reabsorption, which minimizes the fall in arterial pH. This 
increase in proximal bicarbonate transport also promotes the passive 
reabsorption of sodium chloride and water, and may contribute to edema 
formation [68]. 
DIAGNOSTIC EVALUATION 
Chest radiograph  
The classic chest radiograph shows enlargement of the central 
pulmonary arteries with attenuation of the peripheral vessels, resulting in 
oligemic lung fields. Right ventricular enlargement (diminished retrosternal 
space) and right atrial dilatation (prominent right heart border) may also be 
seen. Occasionally, the underlying cause of the PHT is apparent on the 
chest radiograph (eg, interstitial lung disease). 
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Electrocardiography  
The electrocardiogram (ECG) may demonstrate signs of right 
ventricular hypertrophy or strain, including right axis deviation, an R wave/S 
wave ratio greater than one in lead V1, incomplete or complete right bundle 
branch block, or increased P wave amplitude in lead II (P pulmonale) due 
to right atrial enlargement . Most ECG signs are specific but not sensitive 
for the detection of right ventricular disease. ECG changes cannot 
determine disease severity or prognosis [82,83]. 
Echocardiography  
Echocardiography is performed to estimate the pulmonary artery 
systolic pressure and to assess right ventricular size, thickness, and 
function. In addition, echocardiography can evaluate right atrial size, left 
ventricular systolic and diastolic function, and valve function, while 
detecting pericardial effusions and intracardiac shunts [84,85]. 
Echocardiography uses Doppler ultrasound to estimate the 
pulmonary artery systolic pressure. This technique takes advantage of the 
tricuspid regurgitation that usually exists. The maximum tricuspid 
regurgitant jet velocity is recorded and the pulmonary artery systolic 
pressure (PASP) is then calculated: 
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     PASP   =   (4  x  TRV squared)  +  RAP 
where TRV is the maximum tricuspid regurgitant jet velocity and RAP is the 
right atrial pressure estimated from the size and respiratory variation of flow 
in the inferior vena cava. Doppler echocardiography is limited when an 
adequate tricuspid regurgitant jet cannot be identified.  
Patients with PHT may have echocardiographic signs of right 
ventricular pressure overload, including paradoxical bulging of the septum 
into the left ventricle during systole and hypertrophy of the right ventricular 
free wall and trabeculae. As the right ventricle fails, there is dilation and 
hypokinesis, septal flattening, right atrial dilation, and tricuspid 
regurgitation. The tricuspid regurgitation is not due to an intrinsic 
abnormality of the tricuspid valve; it is a secondary manifestation of dilation 
of the tricuspid annulus and right ventricle [86]. Other findings associated 
with pulmonary hypertension are pulmonic insufficiency and 
midsystolicclosure of the pulmonic valve [87]. The echocardiographic 
findings of PHT are summarized in the figure. 
Based upon a Doppler echocardiographic study, it can be determined if 
PHT is likely, unlikely, or possible [88]: 
 PHT is likely if the PASP is >50 and the TRV is >3.4 
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 PHT is unlikely if the PASP is ≤36, the TRV is ≤2.8, and there are no 
other suggestive findings 
 PHT is possible with other combinations of findings 
Doppler echocardiography may be misleading in the assessment of 
patients with suspected pulmonary hypertension, especially when an 
inadequate tricuspid regurgitant jet is over-interpreted. This was illustrated 
by an observational study of 65 patients with various types of PHT[89]. The 
pulmonary arterial pressure estimated by Doppler echocardiography was at 
least 10 mmHg higher or lower than that obtained by right heart 
catheterization in 48 percent of patients and, in many cases, the difference 
in pulmonary artery pressure determined by the two modalities was 
significantly greater than 10 mmHg. Overestimation and underestimation of 
pulmonary arterial pressure occurred with similar frequency, although the 
magnitude of the underestimation was greater. A major limitation of the 
study was that catheterization and Doppler echocardiography were not 
performed simultaneously. 
The study supports our opinion that there should be a low threshold 
to evaluate patients with suspected pulmonary hypertension via right heart 
catheterization. Despite its limitations, Doppler echocardiography detects 
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PHT with greater accuracy than clinical history and physical examination 
[90,91]. 
Pulmonary function tests  
Pulmonary function tests (PFTs) are performed to identify and 
characterize underlying lung disease that may be contributing to PHT. An 
obstructive pattern is suggestive of COPD, while restrictive disease 
suggests interstitial lung disease, neuromuscular weakness, or chest wall 
disease.  
It is usually severe interstitial lung disease (with lung volumes below 
50 percent of predicted) or obstructive lung disease that produces PHT. In 
most circumstances, PHT should not be attributed to lung disease if the 
PFTs are only mildly abnormal since PH itself can cause PFT 
abnormalities. As an example, a study of 79 patients with idiopathic 
pulmonary arterial hypertension (IPAH) demonstrated that more than half of 
patients had a mild to moderate decrease of forced expiratory volume in 
one second (FEV1) or forced vital capacity (FVC) compared to age and sex 
matched controls [92]. The diffusing capacity for carbon monoxide (DLCO) is 
usually decreased in PHT[92,93]. 
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Overnight oximetry  
Nocturnal oxyhemoglobin desaturation can be identified by overnight 
oximetry. It is common in patients with PHT and may prompt supplemental 
oxygen therapy during sleep [94]. Overnight oximetry is not an acceptable 
diagnostic test for sleep related breathing disorders, such as obstructive 
sleep apnea.  
Polysomnography   
Polysomnography is the gold standard diagnostic test for sleep 
related breathing disorders, such as obstructive sleep apnea (OSA). It 
should be performed when the clinical suspicion for OSA is high, or the 
results of overnight oximetry are discordant with clinical expectation.  
V/Q scan 
Ventilation-perfusion (V/Q) scanning is used to evaluate patients for 
thromboembolic disease. A normal V/Q scan accurately excludes chronic 
thromboembolic disease with a sensitivity of 96 to 97 percent and a 
specificity of 90 to 95 percent [95]. When the V/Q scan suggests that chronic 
thromboembolic disease exists, pulmonary angiography is necessary to 
confirm the positive V/Q scan and to define the extent of disease. V/Q 
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scans are an important part of the diagnostic evaluation because PHT due 
to chronic thromboembolic disease is potentially reversible with surgery.  
Laboratory tests  
Blood tests performed in the diagnostic evaluation of PHT include: 
 HIV serology to screen for HIV-associated PHT 
 Liver function tests to screen for portopulmonary hypertension 
 Antinuclear antibody (ANA), rheumatoid factor (RF), and 
antineutrophil cytoplasmic antibody (ANCA) titers to screen for PHT 
due to the connective tissue diseases 
In the appropriate clinical setting, laboratory studies looking for evidence 
of chronic hemolytic anemia (eg, sickle cell disease) or schistosomiasis are 
appropriate.  
N-terminal pro-brain natriuretic peptide (NT-proBNP) is the precursor of 
brain natriuretic peptide (BNP). Both peptides are released from the 
myocardial tissue of the right and left ventricle when stretched. Increasing 
evidence suggests that NT-proBNP and BNP are helpful in diagnosing 
heart failure. It has been hypothesized that measurement of either peptide 
may also be helpful in the diagnosis of PHT, since right heart failure often 
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complicates PHT. Preliminary data are promising, although accuracy 
diminishes if renal dysfunction exists [96-99]. NT-proBNP and BNP should not 
be used in the routine diagnostic evaluation of patients with suspected PHT 
until their value is confirmed in larger prospective studies. 
Exercise testing   
Exercise testing is most commonly performed using the six-minute walk 
test (6MWT) or cardiopulmonary exercise testing. The latter can be 
performed with gas exchange measurements, echocardiography, and/or 
right heart catheterization. Exercise testing during the diagnostic evaluation 
of PH serves several purposes: 
 Screens for alternative causes of the patient's symptoms. 
 Detects exercised-induced PHT, which may be an intermediate stage 
that exists between normal and resting PHT[100]. 
 Determines the patient's World Health Organization (WHO) functional 
class [101], which guides therapy. 
 Establishes a baseline from which the response to therapy can be 
measured.  
37 
 
 Provides prognostic information, since a longer distance walked 
during the 6MWT is associated with longer survival [101]. 
Right heart catheterization  
Right heart catheterization is necessary to confirm the diagnosis of 
PHT and accurately determine the severity of the hemodynamic 
derangements. PHT is confirmed if the mean pulmonary artery pressure is 
greater than 25 mmHg at rest [101]. 
Right heart catheterization is also helpful in distinguishing patients 
who have group 2 PHT (PHT due to left heart disease, such as systolic 
dysfunction, diastolic dysfunction, or valvular heart disease) [81]. Such 
patients have a mean pulmonary capillary wedge pressure (PCWP) ≥15 
mmHg, as measured by right heart catheterization. However, the mean 
PCWP alone is insufficient to definitively diagnose group 2 PHT because it 
may be falsely elevated due to dilatation of the pulmonary arteries and 
incomplete "wedging" of the balloon catheter. To avoid this dilemma, 
patients with a mean PCWP ≥15 mmHg should have their left heart filling 
pressure directly assessed by measuring the left ventricular end diastolic 
pressure (LVEDP) via left heart catheterization. Failure to do so means that 
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some patients may be incorrectly diagnosed as having group 2 PHT, which 
has important therapeutic implications. 
The risk of incorrectly diagnosing patients with group 2 PHT on the 
basis of a falsely elevated mean PCWP was demonstrated by a 
retrospective analysis of hemodynamic data from 3926 patients with PHT 
who underwent simultaneous right and left heart catheterization [102]. 
Among the 3346 patients who had a mean PCWP >15 mmHg, 152 patients 
(5 percent) had a normal left ventricular filling pressure, defined as a 
LVEDP ≤15 mmHg. The authors of the study focused on how frequently the 
mean PCWP was ≤15 mmHg when the LVEDP was >15 mmHg, but it 
should be emphasized that the mean PCWP is virtually always less than 
the LVEDP because the latter reflects the pressure at the end of left atrial 
contraction. 
An additional benefit of right heart catheterization is that the presence 
and/or severity of a congenital or acquired left-to-right shunt can be 
confirmed when noninvasive studies are not definitive. 
NATURAL HISTORY 
 The natural history of untreated IPAH is the most extensively studied 
and the focus of this section. The natural history of other types of PHT is 
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variable and depends on the severity of both the PHT and the underlying 
disease. 
Symptomatic patients with IPAH who do not receive treatment have a 
median survival of approximately three years. Symptomatic patients with 
PAH that is associated with another disease (eg, liver disease, systemic 
sclerosis [also called scleroderma]) generally have a worse prognosis than 
patients with IPAH. However, patients with PAH associated with 
Eisenmenger syndrome are an exception because they have a better 
prognosis than patients with IPAH [69-71]. 
Patients with severe PAH or right heart failure die sooner, usually 
within one year without treatment. As an example, patients with IPAH and a 
mean right atrial pressure ≥20 mmHg have a median survival of 
approximately one month [71]. 
Factors that may indicate a poor prognosis include age at 
presentation greater than 45 years, World Health Organization (WHO) 
functional class III or IV, failure to improve to a lower WHO functional class 
during treatment, pericardial effusion, large right atrial size, elevated right 
atrial pressure, septal shift during diastole, decreased pulmonary arterial 
capacitance (ie, the stroke volume divided by the pulmonary arterial pulse 
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pressure), increased N-terminal brain natriuretic peptide level, and perhaps 
hypocapnia[72-78]. 
Patients with PAH who experience cardiac arrest rarely survive. In a 
retrospective study of more than 3000 patients with PAH who required 
cardiopulmonary resuscitation (CPR), only 6 percent survived for 90 days 
[79]. 
PHT IN CRF 
 Though PHT is a common finding in patients with ESRD, very few 
studies are available on the association between PHT and ESRD. All the 
studies show around 30-40% prevalence of PHT in patients with ESRD and 
more prevalence of PHT among those on HD than those on conservative 
management. 
 Studies have been done to find the causative factors of PHT in 
ESRD. Hormonal and metabolic derangement associated with ESRD might 
lead to pulmonary arterial vasoconstriction and an increase of the 
pulmonary vascular resistance [4]. 
Pulmonary artery pressure (PAP) may be further increased by high 
cardiac output resulting from the arteriovenous access itself and also 
worsened by commonly occurring anemia and fluid overload [8]. Subclinical 
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left ventricular dysfunction also occurs in patients with ESRD, and is 
evidenced as abnormal myocardial diastolic rather than systolic dysfunction 
[9]. 
Local vascular tone and function of pulmonary vessels are regulated 
by the balance between vasodilators, such as nitric oxide, and 
vasoconstrictors, such as thromboxane [10]. Patients with CRF show an 
endothelial dysfunction related to defective nitric oxide activity, which is not 
corrected by hemodialysis (HD) [11]. Increased brain natriuretic hormone is 
associated with age, left ventricular hypertrophy, renal failure, and PHT. N-
terminal pro-brain natriuretic peptide (NT-proBNP) is a byproduct of brain 
natriuretic peptide (BNP) that has been shown to be of prognostic value in 
PHT [15]. 
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METHODOLOGY 
Study Method 
 The study was conducted on patients attending the in-patient/out-
patient department of nephrology in PSG hospital. All patients with a 
diagnosis of ESRD where taken up for the study after the application of the 
inclusion and exclusion criteria and after obtaining consent. These patients 
were divided into two groups – those who receive dialysis and those on 
conservative management. 
 The biochemical data collected were the average of the last six 
readings.ECG, CXR and echocardiography to assess PHT were done to 
those patients who were selected to be included in the study. 
Study Place 
 The study was conducted in PSG Hospitals, Coimbatore. 
Study Population 
 Patients diagnosed with end stage renal disease presenting to PSG 
hospitals during a time period of 6 months were included in the study after 
the application of inclusion and exclusion criteria. 
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Study Period 
 The study was conducted during the time period of April 2010 to 
October 2010. All patients with a diagnosis of ESRD attending the 
Nephrology department who gave consent to be included in the study were 
included during this time period. Total of 73 patients were studied. 
Inclusion Criteria 
 ESRD patients on HD or conservative management were selected. 
ESRD due to all etiologies and patients of all age groups were selected. 
Exclusion Criteria 
 COPD  
 Parenchymal Lung Disease  
 Chest Wall Disease  
 Previous history of PHT  
 Previous pulmonary embolism  
Smoker ( >5 pack years) 
 Collagen Vascular Disease  
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  LV EF <50%  
  Significant mitral/aortic valve disease  
HD patients were being treated with standard bicarbonate dialysis for 
4 hours, 3 times a week. Subjects gave their informedconsent and the 
study protocol was approved by the institute’sCommittee on Human 
Research. 
ESRD: Established kidney failure (GFR <15 mL/min/1.73 m2, or permanent 
renal replacement therapy (RRT) 
Thorough medical history and clinical examination: A completehistory 
was recorded with special emphasis to detect any clinical condition that 
predisposes to PHT, comorbidities, andhistory of renal disease (etiology of 
renal failure, age at onset, durationof HD therapy, and access location, 
brachial or radial). 
Chest radiography and a standard 12-lead ECG: ECG 
findingssuggestive of PHT were as follows: 
(1) right axis deviation 
(2) a tall R-wave and small S-wave with a R/S ratio >1 in lead V1 
(3) qR complex in lead V1 
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(4) rSR’pattern in lead V1 
(5) largeS-wave and small R-wave with R/S ratio <1 in lead V5 or V6 
(6) S1, S2, S3 pattern.  
ST-T segment wave depression and inversion are often present in 
the right precordial leads. Right atrial enlargementis manifested as a tall P-
wave (2.5 mm) in leads II, III,and AVF and frontal P-axis of 75°. 
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The main pulmonary artery and branch pulmonary arteries are more prominent and so is the 
right atrial contour.The striking feature in this chest X-ray is the remarkably prominent main 
pulmonary artery segment (MPA). 
 
Laboratory investigations:The mean values from the 6 monthspreceding 
the echo study were presented for urea, creatinine,hemoglobin, calcium, 
phosphorus and alkaline phosphatase. 
Doppler echocardiography: Two-dimensional and M-
modeechocardiography were performed in all patients within 4 hours 
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followingdialysis when the patients were at optimal dry weight accordingto 
hydration status, blood pressure and weight. Cardiac dimensions were 
measured according to theguidelines of the American Society of 
Echocardiography. Systolic right ventricular (or pulmonary artery) pressure 
wascalculated using the modified Bernoulli equation: PAP = 4 X 
(tricuspidsystolic jet) 2 + 10 mm Hg (estimated right atrial pressure). Stroke 
volume estimated from the left ventricular outflowtract velocity time integral 
X diameter cardiac output was calculatedby multiplying the stroke volume 
by theheart rate. PHT was defined as a systolic PAP > 35 mm Hg 
 
Echocardiogram demonstrating dilatation of the right atrium and ventricles on an apical four-
chamber view. The left ventricle chamber dimensions are normal. 
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RESULTS 
 
Etiology of ESRD 
Etiology Group 1 Group 2 
DM 8(21.6%) 11(30.55%) 
SHT 8(21.6%) 8(22.22%) 
Glomerulonephritis 5(13.5%) 5(13.88%) 
Intestitial Nephritis 3(8.10%) 3(8.33%) 
Unknown 5(13.5%) 4(11.11%) 
Drug Induced 2(5.40%) 3(8.33%) 
Obstructive 
Uropathy 
2(5.40%) 0 
Chronic 
Pyelonephritis 
1(2.70%) 0 
SLE 2(5.40%) 2(5.55%) 
PAN 1(2.70%) 0 
 
Group 1: Patients on HD 
Group 2: Patients on conservative management 
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Figure 1: Etiology of ESRD of group 1 
 
 
 
Figure 2: Etiology of ESRD of group 2 
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Demographic and dialysis data (Average) 
 
Variable Group 1 Group 2 
Age 55.94 55.75 
Gender  
 Males 20 22 
Females 17 14 
Duration of dialysis 18.91 - 
AV access location  
 Radial 21 22 
Brachial 16 14 
ECG  
 Positive 7 3 
Negative 30 33 
 
Group 1: Patients on HD 
Group 2: Patients on conservative management 
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Percentage of PHT positive patients among the two groups 
 
 
 
 
Group 1: 35% have PHT 
Group 2: 28% have PHT 
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Biochemical data of groups 1 and 2 (Average) 
 
Variable Group 1 Group 2 p 
value 
Urea 153.24 83.05 <0.01 
Creatinine 8.79 3.99 <0.01 
Hb 9.79 10.48 <0.01 
Calcium 8.54 9.26 <0.01 
Phosphorus 5.27 4.80 <0.01 
Alk Phosphatase 334.43 135.30 <0.01 
 
 
Group 1: Patients on HD 
Group 2: Patients on conservative management 
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Data of pulmonary hypertensive and non-hypertensive 
groups 
 
Variables PAH + PAH - p value 
Age 61.30 53.04 <0.01 
 
Sex 
Male 14 27  
Female 9 22  
Location 
of AVF 
Brachial 9(39.13%) 20(40.81%)  
Radial 14(60.87%) 29(59.19%)  
Urea 159.95 100.61 <0.01 
Creatinine 7.68 5.90 <0.01 
Hb 9.84 10.27 0.11 
Calcium 8.66 9.03 0.08 
Phosphorus 5.19 4.98 0.18 
Alk Phosphatase 314.52 201.63 <0.01 
 
ECG 
Positive 10 0  
Negative 13 49  
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DISCUSSION 
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DISCUSSION 
PHT in HD patients and in patients with ESRD in the pre-dialysis 
stage were studied and elevated pulmonary artery systolic pressure (>35 
mm Hg) was found in 35% in group 1 and 28% in group 2. The total 
incidence was 31.5% among ESRD patients. 
Results show that PHT is more common among those on 
hemodialysis than those who are on conservative management. The 
causeof a higher PAP in group 1 may be related to the process of HD or 
the hemodynamic changes caused by AVF.The process of HD itself may 
be a contributing factor for elevated PAP, but the exact cause is not known 
and vasoconstrictors such asendothelin may be involved. Microbubble 
emboli are another cause. In addition, HD causes recurrent episodes of 
hypoxemia due to partial blockage of the pulmonary capillary bed by white 
cells or silicone microemboli. Recurrent hypoxemia is associated with 
elevation of PAP. 
Other studies have found a significant difference between groups 1 
and 2 with regard to Thromboxane B2 and pro-BNP. The increase of TXB 2 
in the HD group may be related to the process of HD which induces a 
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detectable extracorporeal increaseof TXB 2 through blood membrane 
interaction causingdegranulation of neutrophils. NT-proBNP is possibly 
largely eliminated by glomerular filtration only, so its level is elevated in 
patients with renal failure. 
In this study, patients with PHT have a significantly higher age than 
those without PHT. They also have higher levels of serum urea and serum 
creatinine.The effect of uremic toxin on PAP had been postulated as an 
etiological factor in HD-associated PHT through endothelial dysfunction 
that has been described in PHT and uremia, which diminishes the 
vasodilatation response to the arteriovenous access-induced elevated 
cardiac output. 
Patients with PHT show no significant difference from those without 
regarding hemoglobin, serum calcium and serum phosphorus. Although 
anemia is associated with a compensatory increased cardiac output and is 
expected to be one of the causes of increased cardiac output, it seems that 
its contribution is minimal in patients with PHT. This study also shows a 
significantly elevated alkaline phosphatase level in patients with PHT the 
significance of which is not yet known. 
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Limitations: 
 AV fistula flow velocities were not studied since compression of the 
AVF can lead to closure of the fistula. 
 Thromboxane B2, NT Pro-BNP and Parathormone levels were not 
studied due to financial reasons. 
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CONCLUSION 
  
 This study shows that PHT is very common in ESRD patients. 
a. 31.5% of total patients (73) with ESRD had PHT 
b. 35% of 37 patients on HD had PHT 
c. 28% of 36 patients on conservative management had PHT 
 
  Also, PHT is much more common in ESRD patients receiving HD than 
those on conservative management. 
 
 Since pulmonary arterial hypertension usually presents at a very late 
stage, early diagnosis is a key to proper management and a better 
outcome.  
 
 Estimation and follow-up of PAP using doppler echocardiography may 
be indicated in all patients with ESRD undergoing HD via an 
arteriovenous access. 
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PROFORMA 
 
Pulmonary Hypertension in ESRD 
 
 
Name         :                                                      IP/OP NO. : 
Age/Sex     : 
 
Cause of Renal Failure:                         Duration of AVF:  
Duration of ESRD:                      Location of AVF: 
         
 
History of Lung Disease 
 
COPD:     Parenchymal Lung Disease: 
Previous history of PHT:    Chest Wall Disease:  
Previous pulmonary embolism:    Collagen Vascular Disease: 
 Smoker (>5 pack years):   Significant mitral/aortic valve disease: 
LV EF <50%:  
 
 
General Examination 
 
CVS:  
       BP: 
RS:   
       PR: 
P/A:  
        
ECG:   
       
 CXR: 
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Biochemical Data 
 
    1     2     3      4     5      6 Average 
Urea        
Creatinine        
Hemoglobin        
Calcium        
Phosphorus        
Alk. 
Phosphotase 
       
 
 
Echocardiogram 
 
Presence of valvular heart disease: 
 
LVEF: 
 
PAP: 
